title: Oncolytic virotherapy synergism with signaling inhibitors: Rapamycin increases myxoma virus tropism for human tumor cells.
abstract: Myxoma virus is a rabbit-specific poxvirus pathogen that also exhibits a unique tropism for human tumor cells and is dramatically oncolytic for human cancer xenografts. Most tumor cell lines tested are permissive for myxoma infection in a fashion intimately tied to the activation state of Akt kinase. A host range factor of myxoma virus, M-T5, directly interacts with Akt and mediates myxoma virus tumor cell tropism. mTOR is a regulator of cell growth and metabolism downstream of Akt and is specifically inhibited by rapamycin. We report that treatment of nonpermissive human tumor cell lines, which normally restrict myxoma virus replication, with rapamycin dramatically increased virus tropism and spread in vitro. This increased myxoma replication is concomitant with global effects on mTOR signaling, specifically, an increase in Akt kinase. In contrast to the effects on human cancer cells, rapamycin does not increase myxoma virus replication in rabbit cell lines or permissive human tumor cell lines with constitutively active Akt. This indicates that rapamycin increases the oncolytic capacity of myxoma virus for human cancer cells by reconfiguring the internal cell signaling environment to one that is optimal for productive virus replication and suggests the possibility of a potentially therapeutic synergism between kinase signaling inhibitors and oncolytic poxviruses for cancer treatment.
authors.affiliation: Biotherapeutics Research Group, Robarts Research Institute, Department of Microbiology and Immunology, University of Western Ontario, London, Ontario N6G 2V4, Canada.
authors.forename: Marianne M
authors.initials: MM
authors.lastname: Stanford
authors.forename: John W
authors.initials: JW
authors.lastname: Barrett
authors.forename: Steven H
authors.initials: SH
authors.lastname: Nazarian
authors.forename: Steven
authors.initials: S
authors.lastname: Werden
authors.forename: Grant
authors.initials: G
authors.lastname: McFadden
mesh_terms: D045744:Cell Line, Tumor; D006801:Humans; D009233:Myxoma virus / Q000502:physiology*; D009369:Neoplasms / Q000628:therapy*; D050130:Oncolytic Virotherapy / Q000379:methods*; D050504:Oncolytic Viruses / Q000378:metabolism*; D020123:Sirolimus; D014764:Viral Proteins / Q000378:metabolism*
chemical_list: D014764:Viral Proteins; D020123:Sirolimus